Expert Ratings for Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) received five somewhat bullish analyst ratings in the last quarter, with no bearish or indifferent ratings. The average 12-month price target among these analysts is $98.00, with a high of $130.00 and a low of $72.00. This target represents an 8.13% decrease from the previous average target of $106.67. Analyst ratings are important as they provide guidance on stock performance based on financial analysis and insider information.
December 08, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ultragenyx Pharmaceutical has received a consensus somewhat bullish rating from analysts, with an average price target of $98.00, which is lower than the previous target of $106.67.
The somewhat bullish ratings indicate a positive sentiment among analysts, which could be favorable for RARE in the short term. However, the decrease in the average price target may temper investor expectations, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100